# Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

> **NCT01403064** · PHASE2 · TERMINATED · sponsor: **CSL Behring** · enrollment: 76 (actual)

## Conditions studied

- Oral Mucositis

## Interventions

- **BIOLOGICAL:** ALD518
- **DRUG:** 0.9% saline

## Key facts

- **NCT ID:** NCT01403064
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2013-04
- **Final completion:** 2014-03
- **Target enrollment:** 76 (ACTUAL)
- **Why stopped:** due to lack of efficacy
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01403064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01403064, "Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01403064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*